---
title: "Insulet and Calm Partner to Offer Mindfulness Tools for People Living with Diabetes"
id: "endocrine-news-0-pharma-friday-july-17-2026"
canonical_url: "https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-july-17-2026"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "Endocrine News"
source_url: "https://endocrinenews.endocrine.org/pharma-friday-july-17-2026/"
published_at: "2026-07-17T16:27:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Insulet and Calm Partner to Offer Mindfulness Tools for People Living with Diabetes
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-july-17-2026
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** Endocrine News
- **Source URL:** [Original Journal Publication](https://endocrinenews.endocrine.org/pharma-friday-july-17-2026/)
- **Published At:** 2026-07-17T16:27:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Insulet Corporation announced a global partnership with Calm on July 14 to deliver emotional well‑being resources tailored to people living with diabetes, caregivers, and healthcare professionals. - The collaboration marks Calm’s first integrated content partnership with a MedTech company and launches a bespoke collection called The Mind in Range Collection. - The collection includes a Sleep Story narrated by Omnipod user Lila Moss, guided meditations, and a breathing exercise, all designed for the diabetes community and available free on Calm’s app and website. - Insulet’s Omnipod brand is the company’s flagship insulin pump technology; the partnership reflects Insulet’s stated emphasis on whole‑person care and reducing cognitive burden for patients. - Insulet cites global research showing mental health gaps in diabetes care: 66% of people with diabetes and 46% of caregivers report poor sleep tied to diabetes‑related stress; 62% (type 1) and 60% (type 2) want mental health and mindfulness support. - Among users of mindfulness tools, Insulet’s data report 39% experienced less stress and 33% reported less anxiety and fewer sleep problems. - Insulet and Calm reference evidence that mindfulness‑based stress reduction can reduce stress over time for people with diabetes; the companies aim to normalize well‑being conversations and make mindfulness accessible. - The initiative will roll out globally with bespoke content available on Calm and Calm Sleep apps and promoted across Omnipod and Calm channels; materials are accessible via omnipod.com/calm. - The announcement includes quotes from Insulet chief growth officer Manoj Raghunandanan and Calm Chief Clinical Officer Dr. Chris Mosunic emphasizing the partnership’s focus on emotional well‑being, though full research methodology and data sources were not detailed in the source article.
## Clinical Analysis & Structured Key Points
Skip to content Endocrine News Topics Practice Lab Notes Advocacy InTouch Podcast Search CURRENT ISSUE DOWNLOAD LOGIN Pharma Friday – July 17, 2026 New announcement from Insulet about its partnership with Calm July 17, 2026 PRINT THIS ARTICLE SHARE THIS ARTICLE An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community On July 14, Insulet Corporation announced a global partnership with Calm, a leading consumer mental health company, to provide emotional well-being resources for people living with diabetes, their caregivers, and healthcare professionals. Insulet is known for its insulin pump technology, specifically its Omnipod® brand of products. The partnership launches Calm’s first-ever integrated content partnership and collection with a MedTech company, introducing bespoke mindfulness content, The Mind in Range Collection. The collection includes short meditations, a breathing exercise, and a new Calm Sleep Story, designed specifically for the diabetes community. “The unmet needs and daily realities of people living with diabetes shape how we innovate and who we choose to partner with,” said Manoj Raghunandanan, chief growth officer at Insulet. “Living with this condition requires constant decisions, and over time that responsibility can create real stress and anxiety. Global data suggest that nearly 80% of people living with diabetes suffer burnout from the emotional strain and demands of daily management. We hold ourselves to a clear standard: do more for people while asking less of them. Partnering with Calm recognizes the emotional dimension of diabetes and expands the support we provide beyond physical outcomes.” Available on the Calm app and website beginning today, the collection features a suite of free-to-access mindfulness tools created for the diabetes community, which includes: A Sleep Story narrated by Lila Moss, fashion model and Omnipod user living with type 1 diabetes. Lila shares a soothing narrative that helps listeners unwind and feel supported as they drift to sleep A series of guided meditations to help manage stress and restore balance during moments of overwhelm A breathing exercise designed to calm the mind and body, ideal for quick resets throughout the day Global research3 from Insulet shows most people with diabetes want more holistic care—yet mental health needs remain overlooked. 66% of people with diabetes and 46% of caregivers report poor‑quality sleep driven by diabetes‑related stress and anxiety 62% of people with type 1 diabetes and 60% with type 2 diabetes say they want support that includes mental health and mindfulness Among those using mindfulness tools, 39% report less stress and 33% less anxiety and fewer sleep problems Studies show that mindfulness-based stress reduction can meaningfully reduce stress for people with diabetes over time. Through this partnership, Insulet and Calm aim to normalize conversations around well-being and mental health in diabetes care and make mindfulness simple and accessible. “Mindfulness can play a powerful role in improving quality of life for people living with diabetes,” said Dr. Chris Mosunic, Calm Chief Clinical Officer. “By combining Calm’s expertise in this area with Insulet’s leadership in diabetes technology, we’re delivering tools and support that reduce cognitive burden and relieve emotional stress to improve mental wellness.” This partnership reinforces Insulet’s position as a brand that prioritizes whole-person care and empowers healthcare professionals with credible, evidence-based resources to support their patients’ emotional well-being. The initiative will roll out globally with bespoke content available on the Calm and Calm Sleep apps and promoted across Omnipod and Calm channels throughout the year. To learn more and explore the free guided meditations, breathing exercise, and Lila Moss’s new sleep story, visit the Omnipod × Calm page at omnipod.com/calm. *Inclusion in Pharma Fridays does not suggest an endorsement by Endocrine News or the Endocrine Society. TOPICS IN THIS ARTICLE: PHARMA FRIDAYS ←The Human Side of Endocrinology: From Learner to Advocate RELATED ARTICLES Eureka! The Top Endocrine Discoveries of 2024 – Part V DECEMBER 30, 2024 Eureka! The Top Endocrine Science of 2024 – Part IV DECEMBER 26, 2024 Eureka! The Top Endocrine Science of 2024 – Part III DECEMBER 23, 2024 ADVERTISEMENT VIEW ARCHIVES ADVERTISEMENT ADVERTISEMENT Join the Global Movement Advancing Endocrine Science and Medicine Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities. Join Today Research Health Topics Adrenal Bone and Mineral Cardiometabolic Diabetes Endocrine Disruptors Head Glands Kidney Issues Neoplasia and Cancer Obesity Pancreas Reproductive Issues Thyroid Transgender Health Patient Populations Health Disparities Men’s Health Pediatric Health Women’s Health Topics Practice Lab Notes Advocacy InTouch Podcast About Endocrine News Advertise in Endocrine News Contact Us About the Endocrine Society Privacy Policy Terms of Use © 2026 Copyright Endocrine Society. All rights reserved. 2055 L Street NW, Suite 600 | Washington, DC 20036 Phone: 202.971.3636 | Toll-free: 888.363.6274 Website Design and Development by Matrix Group International Back to Top
## Related Clinical Research

- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)
- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)
- [Waist circumference predicts mortality more than BMI in adults 65+: study findings](https://medichelpline.com/clinical-feed/medical-news-today-0-bmi-vs-waist-size-study-finds-belly-fat-matters-more-than-weight-for-death-risk.md)
- [SGLT2 Inhibitors and Rheumatoid Arthritis Risk in Type 2 Diabetes: Summary of Reported Emulated Ta](https://medichelpline.com/clinical-feed/frontiers-in-immunology-19-the-association-between-sglt2-inhibitors-and-rheumatoid-arthritis-risk-in-type.md)
- [INSULIN Act: Bipartisan House Bill to Cap Insulin Cost and Improve Access](https://medichelpline.com/clinical-feed/endocrine-news-0-endocrine-society-applauds-introduction-of-bipartisan-bill-to-address-insulin.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.